PepGen Reports Early Data for DM1 Drug
The experimental myotonic dystrophy type 1 treatment showed its most promising early results so far by one key measure in a small patient group.
Updated on Nov. 10, 2026 in Diabetes

Biotech company PepGen reported early trial data for its experimental drug for myotonic dystrophy type 1, showing the most promising results by one key measure. The early data come from six patients treated for 12 weeks.
Why it matters
Myotonic dystrophy type 1 affects over 100,000 people in the U.S. and Europe and typically causes loss of muscle control and strength beginning around adolescence. The mixed results across competitors show how difficult the disease is to treat.
The results come from six patients treated for 12 weeks, a sample too small to establish efficacy. The source does not report whether the improvement on the key measure is statistically significant or how it compares to placebo.
The players
PepGen
PepGen is a biotech company developing treatments for myotonic dystrophy type 1.
Novartis
Novartis is a Swiss multinational pharmaceutical company that acquired a DM1 drug through its buyout of Avidity Biosciences.
Dyne Therapeutics
Dyne Therapeutics is a biotech company developing treatments for muscle diseases and is close to completing a pivotal trial for a DM1 drug.
The details
PepGen's experimental drug is delivered by infusion and was tested in six patients over 12 weeks. Separately, Novartis's DM1 drug, acquired through its $12 billion buyout of Avidity Biosciences, failed to improve a key measure of muscle control in a Phase 3 trial.
Timeline
Tuesday, November 10, 2026: PepGen announced its early DM1 trial data.
Health Landscape
PepGen's early data arrives as Novartis's Phase 3 DM1 trial failed to improve a key muscle control measure, a setback for a disease with no approved disease-modifying treatments. Dyne Therapeutics' pivotal DM1 trial is nearing completion, which will show whether competing approaches can succeed where Novartis did not.
For people living with DM1, these trials signal that new treatment options are in development, though none is yet approved. The mixed results mean patients and families should continue discussing current symptom-management options with their physicians.
The takeaway
Early results from small trials are a first signal, not proof of benefit. Readers following DM1 should watch for larger, controlled studies before drawing conclusions about any new therapy.
Further reading
Explore more on Diabetes to see how rare genetic disease research fits into the broader landscape of metabolic and chronic conditions.



